| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
57,680,000 |
| Market
Cap: |
1.75(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.05 - $32.15 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Protagonist Therapeutics is a clinical-stage biopharmaceutical company with various peptide-based new chemical entities in different stages of development, all derived from Co.'s proprietary technology platform. Co.'s clinical programs address two main categories of diseases; hematology and blood disorders, and inflammatory and immunomodulatory diseases. Co.'s main clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. PN-943 is an investigational, orally delivered, gut-restricted alpha-4-beta-7 specific integrin antagonist for inflammatory bowel disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
93,396 |
173,396 |
175,244 |
175,244 |
| Total Sell Value |
$2,858,339 |
$4,489,339 |
$4,519,351 |
$4,519,351 |
| Total People Sold |
3 |
4 |
5 |
5 |
| Total Sell Transactions |
6 |
8 |
9 |
9 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Liu David Y |
Chief Scientific Officer |
• – – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
68,657 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
31,250 |
508,408 |
|
- |
|
| Kalkofen Donald A. |
Chief Financial Officer |
• – – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
18,521 |
|
- |
|
| Gupta Suneel |
Chief Development Officer |
• – – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
77,656 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2021-12-21 |
4 |
S |
$32.14 |
$482,171 |
D/D |
(15,000) |
477,158 |
|
70% |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2021-09-21 |
4 |
OE |
$4.21 |
$168,400 |
D/D |
40,000 |
492,158 |
|
- |
|
| Liu David Y |
Chief Scientific Officer |
• – – |
2021-08-17 |
4 |
AS |
$47.56 |
$702,889 |
D/D |
(14,779) |
58,254 |
|
-30% |
|
| Liu David Y |
Chief Scientific Officer |
• – – |
2021-08-17 |
4 |
OE |
$0.87 |
$8,700 |
D/D |
10,000 |
73,033 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
451,144 |
|
- |
|
| Saks Samuel R |
Chief Medical Officer |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
14,000 |
|
- |
|
| Liu David Y |
Chief Scientific Officer |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
62,427 |
|
- |
|
| Kalkofen Donald A. |
Chief Financial Officer |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
10,386 |
|
- |
|
| Gupta Suneel |
Chief Development Officer |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
63,987 |
|
- |
|
| Noonberg Sarah B. |
Director |
– • – |
2021-02-11 |
4 |
AS |
$25.09 |
$92,833 |
D/D |
(3,700) |
0 |
|
72% |
|
| Noonberg Sarah B. |
Director |
– • – |
2021-02-11 |
4 |
A |
$6.98 |
$25,826 |
D/D |
3,700 |
3,700 |
|
- |
|
| Noonberg Sarah B. |
Director |
– • – |
2021-02-10 |
4 |
AS |
$25.42 |
$119,722 |
D/D |
(4,700) |
0 |
|
76% |
|
| Noonberg Sarah B. |
Director |
– • – |
2021-02-10 |
4 |
A |
$6.98 |
$32,806 |
D/D |
4,700 |
4,700 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2021-01-19 |
4 |
AS |
$24.60 |
$611,105 |
D/D |
(24,846) |
426,144 |
|
41% |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2021-01-19 |
4 |
OE |
$4.21 |
$54,730 |
D/D |
13,000 |
450,990 |
|
- |
|
| Khosla Chaitan Phd |
Director |
– • – |
2020-08-11 |
4 |
AS |
$17.19 |
$42,952 |
D/D |
(2,499) |
0 |
|
48% |
|
| Khosla Chaitan Phd |
Director |
– • – |
2020-08-11 |
4 |
OE |
$1.89 |
$4,723 |
D/D |
2,499 |
2,499 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2020-04-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
437,990 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2020-03-20 |
4 |
OE |
$1.89 |
$18,900 |
D/D |
10,000 |
439,990 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2020-03-12 |
4 |
OE |
$1.16 |
$21,279 |
D/D |
18,344 |
429,990 |
|
- |
|
| Selick Harold E |
Director |
– • – |
2020-03-12 |
4 |
B |
$6.70 |
$80,400 |
D/D |
12,000 |
15,310 |
2.39 |
153% |
|
166 Records found
|
|
Page 3 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.13 (0.43%) 
